Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Redefining osteoporosis treatment: Who to treat and how long to treat Lewiecki EM; Silverman SLArq Bras Endocrinol Metabol 2006[Aug]; 50 (4): 694-704Osteoporosis is a common disease that is associated with increased risk of fractures and serious clinical consequences. Bone mineral density (BMD) testing is used to diagnose osteoporosis, estimate the risk of fracture, and monitor changes in BMD over time. Combining clinical risk factors for fracture with BMD is a better predictor of fracture risk than BMD or clinical risk factors alone. Methodologies are being developed to use BMD and validated risk factors to estimate the 10-year probability of fracture, and then combine fracture probability with country-specific economic assumptions to determine cost-effective intervention thresholds. The decision to treat is based on factors that also include availability of therapy, patient preferences, and co-morbidities. All patients benefit from nonpharmacological lifestyle treatments such a weight-bearing exercise, adequate intake of calcium and vitamin D, fall prevention, avoidance of cigarette smoking and bone-toxic drugs, and moderation of alcohol intake. Patients at high risk for fracture should be considered for pharmacological therapy, which can reduce fracture risk by about 50%.|*Bone Density[MESH]|Accidental Falls/prevention & control[MESH]|Adult[MESH]|Aged[MESH]|Bone Density Conservation Agents/*therapeutic use[MESH]|Diphosphonates/*therapeutic use[MESH]|Female[MESH]|Fractures, Bone/*etiology/prevention & control[MESH]|Glucocorticoids/adverse effects[MESH]|Humans[MESH]|Long-Term Care[MESH]|Male[MESH]|Middle Aged[MESH]|Osteoporosis/complications/*drug therapy/prevention & control[MESH]|Patient Selection[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Time Factors[MESH] |